Understanding the molecular causes of Parkinson's disease

Trends in Molecular Medicine

Volumn 12, Issue 11, 2006, Pages 521-528

  Wood Kaczmar, A ^a   Gandhi, S ^a   Wood, N W ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; LEUCIN RICH REPEAT KINASE 2; PARKIN; PTEN INDUCED PUTATIVE KINASE 1; UNCLASSIFIED DRUG;

AUTOSOMAL DOMINANT DISORDER; AUTOSOMAL RECESSIVE DISORDER; CELL DEGENERATION; CLINICAL FEATURE; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC NERVE CELL; GENE EXPRESSION; GENE FUNCTION; GENE LOCUS; GENE MUTATION; HUMAN; NEUROPATHOLOGY; NONHUMAN; ONSET AGE; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW;

ADULT; ALPHA-SYNUCLEIN; ANIMALS; CELL DEATH; CHROMOSOME ABERRATIONS; HUMANS; MIDDLE AGED; MODELS, BIOLOGICAL; MUTATION; OXIDATIVE STRESS; PARKINSON DISEASE; PHOSPHORYLATION; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; UBIQUITIN-PROTEIN LIGASES;

EID: 33750370804     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2006.09.007     Document Type: Review

References (90)

1. Polymeropoulos M.H., et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276 (1997) 2045-2047
2. Cookson M.R. The biochemistry of Parkinson's disease. Annu. Rev. Biochem. 74 (2005) 29-52
3. Farrer M., et al. Comparison of kindreds with parkinsonism and α-synuclein genomic multiplications. Ann. Neurol. 55 (2004) 174-179
4. Nishioka K., et al. Clinical heterogeneity of α-synuclein gene duplication in Parkinson's disease. Ann. Neurol. 59 (2006) 298-309
5. Singleton A.B., et al. α-Synuclein locus triplication causes Parkinson's disease. Science 302 (2003) 841
6. Maraganore D.M., et al. Collaborative analysis of α-synuclein gene promoter variability and Parkinson disease. JAMA 296 (2006) 661-670
7. Iwai A., et al. The precursor protein of non-A β component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14 (1995) 467-475
8. Jakes R., et al. Identification of two distinct synucleins from human brain. FEBS Lett. 345 (1994) 27-32
9. Mori F., et al. Demonstration of α-synuclein immunoreactivity in neuronal and glial cytoplasm in normal human brain tissue using proteinase K and formic acid pretreatment. Exp. Neurol. 176 (2002) 98-104
10. Lotharius J., and Brundin P. Pathogenesis of Parkinson's disease: dopamine, vesicles and α-synuclein. Nat. Rev. Neurosci. 3 (2002) 932-942
11. Sidhu A., et al. The role of (-synuclein in both neuroprotection and neurodegeneration. Ann. N. Y. Acad. Sci. 1035 (2004) 250-270
12. Abeliovich A., et al. Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25 (2000) 239-252
13. Cabin D.E., et al. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking α-synuclein. J. Neurosci. 22 (2002) 8797-8807
14. Chandra S., et al. Double-knockout mice for α- and β-synucleins: effect on synaptic functions. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 14966-14971
15. Fernagut P.O., and Chesselet M.F. Alpha-synuclein and transgenic mouse models. Neurobiol. Dis. 17 (2004) 123-130
16. Cole N.B., et al. Lipid droplet binding and oligomerization properties of the Parkinson's disease protein α-synuclein. J. Biol. Chem. 277 (2002) 6344-6352
17. Outeiro T.F., and Lindquist S. Yeast cells provide insight into α-synuclein biology and pathobiology. Science 302 (2003) 1772-1775
18. Bussell Jr. R., et al. Helix periodicity, topology, and dynamics of membrane-associated α-synuclein. Protein Sci. 14 (2005) 862-872
19. Kubo S., et al. A combinatorial code for the interaction of α-synuclein with membranes. J. Biol. Chem. 280 (2005) 31664-31672
20. Narayanan V., et al. Fluorescence studies suggest a role for α-synuclein in the phosphatidylinositol lipid signaling pathway. Biochemistry 44 (2005) 462-470
21. Payton J.E., et al. Structural determinants of PLD2 inhibition by α-synuclein. J. Mol. Biol. 337 (2004) 1001-1009
22. Castagnet P.I., et al. Fatty acid incorporation is decreased in astrocytes cultured from α-synuclein gene-ablated mice. J. Neurochem. 94 (2005) 839-849
23. Golovko M.Y., et al. Alpha-synuclein gene deletion decreases brain palmitate uptake and alters the palmitate metabolism in the absence of α-synuclein palmitate binding. Biochemistry 44 (2005) 8251-8259
24. Ellis C.E., et al. Mitochondrial lipid abnormality and electron transport chain impairment in mice lacking α-synuclein. Mol. Cell. Biol. 25 (2005) 10190-10201
25. Chandra S., et al. Alpha-synuclein cooperates with CSPα in preventing neurodegeneration. Cell 123 (2005) 383-396
26. Spillantini M.G., et al. Alpha-synuclein in Lewy bodies. Nature 388 (1997) 839-840
27. Conway K.A., et al. Fibrils formed in vitro from α-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 39 (2000) 2552-2563
28. Serpell L.C., et al. Fiber diffraction of synthetic α-synuclein filaments shows amyloid-like cross-β conformation. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 4897-4902
29. Miller D.W., et al. Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology 62 (2004) 1835-1838
30. Fleming S.M., et al. Genetic mouse models of parkinsonism: strengths and limitations. NeuroRx. 2 (2005) 495-503
31. Feany M.B., and Bender W.W. A Drosophila model of Parkinson's disease. Nature 404 (2000) 394-398
32. Chen L., and Feany M.B. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat. Neurosci. 8 (2005) 657-663
33. Fujiwara H., et al. α-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 4 (2002) 160-164
34. Greenbaum E.A., et al. The E46K mutation in α-synuclein increases amyloid fibril formation. J. Biol. Chem. 280 (2005) 7800-7807
35. Volles M.J., et al. Vesicle permeabilization by protofibrillar α-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40 (2001) 7812-7819
36. Galvin J.E. Interaction of α-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra. Acta Neuropathol. (Berl.) 112 (2006) 115-126
37. Xu J., et al. Dopamine-dependent neurotoxicity of α-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat. Med. 8 (2002) 600-606
38. Conway K.A., et al. Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct. Science 294 (2001) 1346-1349
39. Paisan-Ruiz C., et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44 (2004) 595-600
40. Zimprich A., et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44 (2004) 601-607
41. Khan N.L., et al. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain 128 (2005) 2786-2796
42. Albrecht M. LRRK2 mutations and Parkinsonism. Lancet 365 (2005) 1230
43. Gilks W.P., et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 365 (2005) 415-416
44. Lesage S., et al. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N. Engl. J. Med. 354 (2006) 422-423
45. Ozelius L.J., et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N. Engl. J. Med. 354 (2006) 424-425
46. Galter D., et al. LRRK2 expression linked to dopamine-innervated areas. Ann. Neurol. 59 (2006) 714-719
47. Melrose H., et al. Anatomical localization of leucine-rich repeat kinase 2 in mouse brain. Neuroscience (2006)
48. Simon-Sanchez J., et al. LRRK2 is expressed in areas affected by Parkinson's disease in the adult mouse brain. Eur. J. Neurosci. 23 (2006) 659-666
49. Gloeckner C.J., et al. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum. Mol. Genet. 15 (2006) 223-232
50. West A.B., et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 16842-16847
51. Giasson B.I., et al. Biochemical and pathological characterization of Lrrk2. Ann. Neurol. 59 (2006) 315-322
52. Zhu X., et al. LRRK2 protein is a component of lewy bodies. Ann. Neurol. (2006)
53. Kitada T., et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392 (1998) 605-608
54. Lucking C.B., et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. N. Engl. J. Med. 342 (2000) 1560-1567
55. West A.B., and Maidment N.T. Genetics of parkin-linked disease. Hum. Genet. 114 (2004) 327-336
56. Pramstaller P.P., et al. Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers. Ann. Neurol. 58 (2005) 411-422
57. von Coelln R., et al. Parkin-associated Parkinson's disease. Cell Tissue Res. 318 (2004) 175-184
58. Shimura H., et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 25 (2000) 302-305
59. Kalia S.K., et al. BAG5 inhibits parkin and enhances dopaminergic neuron degeneration. Neuron 44 (2004) 931-945
60. Fallon L., et al. Parkin and CASK/LIN-2 associate via a PDZ-mediated interaction and are co-localized in lipid rafts and postsynaptic densities in brain. J. Biol. Chem. 277 (2002) 486-491
61. Sriram S.R., et al. Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin. Hum. Mol. Genet. 14 (2005) 2571-2586
62. Goldberg M.S., et al. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J. Biol. Chem. 278 (2003) 43628-43635
63. Itier J.M., et al. Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum. Mol. Genet. 12 (2003) 2277-2291
64. Ko H.S., et al. Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death. J. Neurosci. 25 (2005) 7968-7978
65. Palacino J.J., et al. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J. Biol. Chem. 279 (2004) 18614-18622
66. Greene J.C., et al. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 4078-4083
67. Pesah Y., et al. Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress. Development 131 (2004) 2183-2194
68. Kuroda Y., et al. Parkin enhances mitochondrial biogenesis in proliferating cells. Hum. Mol. Genet. 15 (2006) 883-895
69. Chung K.K., et al. S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science 304 (2004) 1328-1331
70. Winklhofer K.F., et al. Inactivation of parkin by oxidative stress and C-terminal truncations: a protective role of molecular chaperones. J. Biol. Chem. 278 (2003) 47199-47208
71. Yao D., et al. Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. Proc. Natl. Acad. Sci. U. S. A. 20 (2004) 101, 10810-10814
72. LaVoie M.J., et al. Dopamine covalently modifies and functionally inactivates parkin. Nat. Med. 11 (2005) 1214-1221
73. Hatano Y., et al. Novel PINK1 mutations in early-onset parkinsonism. Ann. Neurol. 56 (2004) 424-427
74. Valente E.M., et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304 (2004) 1158-1160
75. Klein C., and Schlossmacher M.G. The genetics of Parkinson disease: implications for neurological care. Nat. Clin. Pract. Neurol. 2 (2006) 136-146
76. Silvestri L., et al. Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. Hum. Mol. Genet. 14 (2005) 3477-3492
77. Abou-Sleiman, P. M. et al. (2006) A heterozygous effect for PINK1 mutations in Parkinson's disease? Ann. Neurol. (in press)
78. Beilina A., et al. Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 5703-5708
79. Gandhi S., et al. PINK1 protein in normal human brain and Parkinson's disease. Brain 129 (2006) 1720-1731
80. Petit A., et al. Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson disease-related mutations. J. Biol. Chem. 280 (2005) 34025-34032
81. Clark I.E., et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 441 (2006) 1162-1166
82. Park J., et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 441 (2006) 1157-1161
83. Bonifati V., et al. Linking DJ-1 to neurodegeneration offers novel insights for understanding the pathogenesis of Parkinson's disease. J. Mol. Med. 82 (2004) 163-174
84. Zhang L., et al. Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. Hum. Mol. Genet. 14 (2005) 2063-2073
85. Zhou W., et al. The oxidation state of DJ-1 regulates its chaperone activity toward α-synuclein. J. Mol. Biol. 356 (2006) 1036-1048
86. Choi J., et al. Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases. J. Biol. Chem. 281 (2006) 10816-10824
87. Goldberg M.S., et al. Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron 45 (2005) 489-496
88. Yang Y., et al. Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signalling. Proc. Natl. Acad. Sci. U. S. A. 20 (2005) 102, 13670-13675
89. Kessler K.R., et al. Dopaminergic function in a family with the PARK6 form of autosomal recessive Parkinson's syndrome. J. Neural. Transm. 112 (2005) 1345-1353
90. Khan N.L., et al. Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation. Neurology 64 (2005) 134-136